Moyamoya Disease, a Rare Cause of Recurrent Strokes in an African Sickle Cell Child: Does hydroxyurea have a Role in this Context?
DOI:
https://doi.org/10.6000/1929-4247.2012.01.01.10%20Keywords:
Key words. Moyamoya Stroke Sickle Cell Child, stroke, hydroxyurea.Abstract
Background: Neurological complications are a significant cause of morbidity and mortality in sickle cell patients with reported incidence of stroke in Africa as high as 1·3/100 patient per year [1,2]. There is an association between sickle cell disease (as well as other hemoglobinopathies) and Moyamoya disease [3]. Data on the occurrence of this condition in African sickle patient are scare. Likewise the role of hydroxyurea among patients with both sickle cell anemia and Moyamoya disease in preventing stroke has not yet been studied in Africa.
Case presentation: In the present report, we describe an African child who had a recurrent stroke. She was later diagnosed as having Moyamoya disease while already receiving hydroxyurea.
Conclusion: Moyamoya disease is a rare condition associated with recurrent stroke in African sickle children. The role of hydroxyurea in this context is still unclear.
References
Izuora GI, Kaine WN, Emodi I. Neurological disorders in Nigerian children with homozygous sickle cell anaemia. East Afr Med J 1989; 66: 653-57.
Amayo EO, Owade JN, Aluoch JR, Njeru EK. Neurological complications of sickle cell anaemia at KNH: a five year retrospective study. East Afr Med J 1992; 69: 660-62.
Fryer RH, Chiriboga CA, Feldstein NA. Sickle cell anemia with moyamoya disease. outcome after EDAS procedure. Paediat Neurol 2003; 29: 124-30. http://dx.doi.org/10.1016/S0887-8994(03)00047-X
Smith ER, McClain CD, Heeney M, Scott RM. Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome. Neurosurg Focus 2009; 26(4): E10. http://dx.doi.org/10.3171/2009.01.FOCUS08307
Kawamura K, Cheng Y, Kawamura N, et al. Moyamoya disease In Handbook of Clinical Neurology. Vol 2. Amsterdam, The Netherlands: Elsevier 1989; pp. 293-306.
Kikuta K, Miyamoto S, Kataoka H, et al. An adult case of moyamoya syndrome that developed dural sinus thrombosis associated with protein C deficiency: a case report and literature review. Surg Neurol 2005; 63: 480-84. http://dx.doi.org/10.1016/j.surneu.2004.04.027
Dobson SR, Holden KR, Nietert PJ, Cure JK, Laver JH, Abboud MR. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events. Blood 2002; 99(9): 3144-50. http://dx.doi.org/10.1182/blood.V99.9.3144
Sumoza A, Renate B, Sumoza D, Fairbank V. Hydroxyurea (HU) for Prevention of Recurrent Stroke in Sickle Cell Anemia. Am J Hematol 2002; 71: 161-65. http://dx.doi.org/10.1002/ajh.10205
Greenway A, Russell E, Courtney DT. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload. Am J Hematol 2011; 86: 357-61.
Ware RE, Zimmerman SA, Sylvestre PB. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 2004; 145: 346-52. http://dx.doi.org/10.1016/j.jpeds.2004.04.058
Ware RE, Helms RW. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood 2012; 119: 3925-32. http://dx.doi.org/10.1182/blood-2011-11-392340
Uchino K, Johnston SC, Becker KJ, Tirschwell DL. Moyamoya disease in Washington State and California. Neurology 2005; 65: 956-58. http://dx.doi.org/10.1212/01.wnl.0000176066.33797.82
Chiu D, Shedden P, Bratina P, Grotta JC. Clinical features of moyamoya disease in the United States. Stroke 1998; 29: 1347-51. http://dx.doi.org/10.1161/01.STR.29.7.1347
Baba T, Houkin K, Kuroda S. Novel epidemiological features of moyamoya disease. J Neurol Neurosurg Psychiatry 2008; 79: 900-4. http://dx.doi.org/10.1136/jnnp.2007.130666
Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332(20): 1317-22. http://dx.doi.org/10.1056/NEJM199505183322001
Ware RE, Steinberg MH, Kinney TR. Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia. Am J Hematol 1995; 50(2): 140-3. http://dx.doi.org/10.1002/ajh.2830500211
Pavlakis SG, ProhovnikI PS, DeVivo DC. Neurologic complications of sickle cell disease. Adv Pediatr 1989: 36: 247-76.
Wang SC, Hong JH, Hsueh C, Chiang CS. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease. J Pediatr 1991; 118: 377-82.
Downloads
Published
How to Cite
Issue
Section
License
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .
